Sonnet Biotherapeutics Holdings Inc (NASDAQ:SONN) — Market Cap & Net Worth
Market Cap & Net Worth: Sonnet Biotherapeutics Holdings Inc (SONN)
Sonnet Biotherapeutics Holdings Inc (NASDAQ:SONN) has a market capitalization of $8.60 Million ($8.60 Million) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #27247 globally and #5403 in its home market, demonstrating a -72.31% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Sonnet Biotherapeutics Holdings Inc's stock price $1.26 by its total outstanding shares 6827352 (6.83 Million). Analyse SONN cash flow metrics to see how efficiently the company converts income to cash.
Sonnet Biotherapeutics Holdings Inc Market Cap History: 2015 to 2025
Sonnet Biotherapeutics Holdings Inc's market capitalization history from 2015 to 2025. Data shows change from $4.37 Trillion to $8.60 Million (-73.05% CAGR).
Index Memberships
Sonnet Biotherapeutics Holdings Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.00% | #796 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #2576 of 3165 |
Weight: Sonnet Biotherapeutics Holdings Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Sonnet Biotherapeutics Holdings Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Sonnet Biotherapeutics Holdings Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
8.60x
Sonnet Biotherapeutics Holdings Inc's market cap is 8.60 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.84 Trillion | $41.70 Million | -$9.08 Million | 44051.33x | N/A |
| 2017 | $1.15 Trillion | $41.43 Million | -$6.79 Million | 27762.65x | N/A |
| 2019 | $258.06 Billion | $40.61 Million | -$5.03 Million | 6353.98x | N/A |
| 2019 | $258.06 Billion | $40.61 Million | -$4.87 Million | 6353.98x | N/A |
| 2021 | $6.95 Billion | $483.63K | -$25.01 Million | 14369.40x | N/A |
| 2022 | $1.38 Billion | $349.94K | -$29.77 Million | 3948.80x | N/A |
| 2023 | $95.04 Million | $147.81K | -$18.83 Million | 642.99x | N/A |
| 2024 | $9.97 Million | $18.63K | -$7.44 Million | 535.16x | N/A |
| 2025 | $8.60 Million | $1.00 Million | -$16.11 Million | 8.60x | N/A |
Competitor Companies of SONN by Market Capitalization
Companies near Sonnet Biotherapeutics Holdings Inc in the global market cap rankings as of May 4, 2026.
Key companies related to Sonnet Biotherapeutics Holdings Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Sonnet Biotherapeutics Holdings Inc Historical Marketcap From 2015 to 2025
Between 2015 and today, Sonnet Biotherapeutics Holdings Inc's market cap moved from $4.37 Trillion to $ 8.60 Million, with a yearly change of -73.05%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $8.60 Million | -13.70% |
| 2024 | $9.97 Million | -89.51% |
| 2023 | $95.04 Million | -93.12% |
| 2022 | $1.38 Billion | -80.12% |
| 2021 | $6.95 Billion | -81.48% |
| 2020 | $37.51 Billion | -85.46% |
| 2019 | $258.06 Billion | -54.26% |
| 2018 | $564.23 Billion | -50.95% |
| 2017 | $1.15 Trillion | -37.38% |
| 2016 | $1.84 Trillion | -57.97% |
| 2015 | $4.37 Trillion | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Sonnet Biotherapeutics Holdings Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $8.60 Million USD |
| MoneyControl | $8.60 Million USD |
| MarketWatch | $8.60 Million USD |
| marketcap.company | $8.60 Million USD |
| Reuters | $8.60 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Sonnet Biotherapeutics Holdings Inc
As of December 2, 2025, Sonnet BioTherapeutics Holdings, Inc. was acquired by Hyperliquid Strategies Inc, in a reverse merger transaction. Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that bin… Read more